Agios Pharmaceuticals AGIO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's financing cash flow?
- Agios Pharmaceuticals (AGIO) reported financing cash flow of $2.08M in Q1 2026.
- How has Agios Pharmaceuticals's financing cash flow changed year-over-year?
- Agios Pharmaceuticals's financing cash flow increased by 28.4% year-over-year, from $1.62M to $2.08M.
- What is the long-term trend for Agios Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's financing cash flow has grown at a -67.4% compound annual growth rate (CAGR), from -$765.77M to $8.68M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.